332 related articles for article (PubMed ID: 34481495)
1. A self-amplified nanocatalytic system for achieving "1 + 1 + 1 > 3" chemodynamic therapy on triple negative breast cancer.
Zhou L; Chen J; Sun Y; Chai K; Zhu Z; Wang C; Chen M; Han W; Hu X; Li R; Yao T; Li H; Dong C; Shi S
J Nanobiotechnology; 2021 Sep; 19(1):261. PubMed ID: 34481495
[TBL] [Abstract][Full Text] [Related]
2. Tumor-Specific Expansion of Oxidative Stress by Glutathione Depletion and Use of a Fenton Nanoagent for Enhanced Chemodynamic Therapy.
Chen Q; Zhou J; Chen Z; Luo Q; Xu J; Song G
ACS Appl Mater Interfaces; 2019 Aug; 11(34):30551-30565. PubMed ID: 31397998
[TBL] [Abstract][Full Text] [Related]
3. Catalase abrogates β-lapachone-induced PARP1 hyperactivation-directed programmed necrosis in NQO1-positive breast cancers.
Bey EA; Reinicke KE; Srougi MC; Varnes M; Anderson VE; Pink JJ; Li LS; Patel M; Cao L; Moore Z; Rommel A; Boatman M; Lewis C; Euhus DM; Bornmann WG; Buchsbaum DJ; Spitz DR; Gao J; Boothman DA
Mol Cancer Ther; 2013 Oct; 12(10):2110-20. PubMed ID: 23883585
[TBL] [Abstract][Full Text] [Related]
4. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism.
Silvers MA; Deja S; Singh N; Egnatchik RA; Sudderth J; Luo X; Beg MS; Burgess SC; DeBerardinis RJ; Boothman DA; Merritt ME
J Biol Chem; 2017 Nov; 292(44):18203-18216. PubMed ID: 28916726
[TBL] [Abstract][Full Text] [Related]
5. An NQO1 substrate with potent antitumor activity that selectively kills by PARP1-induced programmed necrosis.
Huang X; Dong Y; Bey EA; Kilgore JA; Bair JS; Li LS; Patel M; Parkinson EI; Wang Y; Williams NS; Gao J; Hergenrother PJ; Boothman DA
Cancer Res; 2012 Jun; 72(12):3038-47. PubMed ID: 22532167
[TBL] [Abstract][Full Text] [Related]
6. Cu-MOF chemodynamic nanoplatform via modulating glutathione and H
Tian H; Zhang M; Jin G; Jiang Y; Luan Y
J Colloid Interface Sci; 2021 Apr; 587():358-366. PubMed ID: 33360905
[TBL] [Abstract][Full Text] [Related]
7. Leveraging an NQO1 Bioactivatable Drug for Tumor-Selective Use of Poly(ADP-ribose) Polymerase Inhibitors.
Huang X; Motea EA; Moore ZR; Yao J; Dong Y; Chakrabarti G; Kilgore JA; Silvers MA; Patidar PL; Cholka A; Fattah F; Cha Y; Anderson GG; Kusko R; Peyton M; Yan J; Xie XJ; Sarode V; Williams NS; Minna JD; Beg M; Gerber DE; Bey EA; Boothman DA
Cancer Cell; 2016 Dec; 30(6):940-952. PubMed ID: 27960087
[TBL] [Abstract][Full Text] [Related]
8. An NQO1- and PARP-1-mediated cell death pathway induced in non-small-cell lung cancer cells by beta-lapachone.
Bey EA; Bentle MS; Reinicke KE; Dong Y; Yang CR; Girard L; Minna JD; Bornmann WG; Gao J; Boothman DA
Proc Natl Acad Sci U S A; 2007 Jul; 104(28):11832-7. PubMed ID: 17609380
[TBL] [Abstract][Full Text] [Related]
9. Tumor-selective use of DNA base excision repair inhibition in pancreatic cancer using the NQO1 bioactivatable drug, β-lapachone.
Chakrabarti G; Silvers MA; Ilcheva M; Liu Y; Moore ZR; Luo X; Gao J; Anderson G; Liu L; Sarode V; Gerber DE; Burma S; DeBerardinis RJ; Gerson SL; Boothman DA
Sci Rep; 2015 Nov; 5():17066. PubMed ID: 26602448
[TBL] [Abstract][Full Text] [Related]
10. Tumor-selective, futile redox cycle-induced bystander effects elicited by NQO1 bioactivatable radiosensitizing drugs in triple-negative breast cancers.
Cao L; Li LS; Spruell C; Xiao L; Chakrabarti G; Bey EA; Reinicke KE; Srougi MC; Moore Z; Dong Y; Vo P; Kabbani W; Yang CR; Wang X; Fattah F; Morales JC; Motea EA; Bornmann WG; Yordy JS; Boothman DA
Antioxid Redox Signal; 2014 Jul; 21(2):237-50. PubMed ID: 24512128
[TBL] [Abstract][Full Text] [Related]
11. H
Yan Y; Han R; Zhang H; Song P; Wei X; Hou Y; Yu J; Tang K
Colloids Surf B Biointerfaces; 2023 Jan; 221():112997. PubMed ID: 36334518
[TBL] [Abstract][Full Text] [Related]
12. Nanocatalytic Theranostics with Glutathione Depletion and Enhanced Reactive Oxygen Species Generation for Efficient Cancer Therapy.
Fu LH; Wan Y; Qi C; He J; Li C; Yang C; Xu H; Lin J; Huang P
Adv Mater; 2021 Feb; 33(7):e2006892. PubMed ID: 33394515
[TBL] [Abstract][Full Text] [Related]
13. PCNA inhibition enhances the cytotoxicity of β-lapachone in NQO1-Positive cancer cells by augmentation of oxidative stress-induced DNA damage.
Su X; Wang J; Jiang L; Chen Y; Lu T; Mendonca MS; Huang X
Cancer Lett; 2021 Oct; 519():304-314. PubMed ID: 34329742
[TBL] [Abstract][Full Text] [Related]
14. Harnessing inorganic nanomaterials for chemodynamic cancer therapy.
Mohammed DF; Madlool HA; Faris M; Shalan BH; Hasan HH; Azeez NF; Abbas FH
Nanomedicine (Lond); 2022 Oct; 17(24):1891-1906. PubMed ID: 36647807
[TBL] [Abstract][Full Text] [Related]
15. Carrier-Free H
Yang T; Zhou M; Gao M; Qin W; Wang Q; Peng H; Yao W; Qiao L; He X
Small; 2023 Feb; 19(7):e2205692. PubMed ID: 36494182
[TBL] [Abstract][Full Text] [Related]
16. A ROS storm generating nanocomposite for enhanced chemodynamic therapy through H
Li Y; Wang J; Zhu T; Zhan Y; Tang X; Xi J; Zhu X; Zhang Y; Liu J
Nanoscale; 2024 May; 16(17):8479-8494. PubMed ID: 38590261
[TBL] [Abstract][Full Text] [Related]
17. Synthesis of Copper Peroxide Nanodots for H
Lin LS; Huang T; Song J; Ou XY; Wang Z; Deng H; Tian R; Liu Y; Wang JF; Liu Y; Yu G; Zhou Z; Wang S; Niu G; Yang HH; Chen X
J Am Chem Soc; 2019 Jun; 141(25):9937-9945. PubMed ID: 31199131
[TBL] [Abstract][Full Text] [Related]
18. Injectable thermo-sensitive hydrogel loaded hollow copper sulfide nanoparticles for ROS burst in TME and effective tumor treatment.
Ning S; Mo J; Huang R; Liu B; Fu B; Ding S; Yang H; Cui Y; Yao L
Front Bioeng Biotechnol; 2023; 11():1191014. PubMed ID: 37200848
[No Abstract] [Full Text] [Related]
19. Modulating endogenous NQO1 levels identifies key regulatory mechanisms of action of β-lapachone for pancreatic cancer therapy.
Li LS; Bey EA; Dong Y; Meng J; Patra B; Yan J; Xie XJ; Brekken RA; Barnett CC; Bornmann WG; Gao J; Boothman DA
Clin Cancer Res; 2011 Jan; 17(2):275-85. PubMed ID: 21224367
[TBL] [Abstract][Full Text] [Related]
20. Enhanced Chemodynamic Therapy Mediated by a Tumor-Specific Catalyst in Synergy with Mitophagy Inhibition Improves the Efficacy for Endometrial Cancer.
Gong X; Wang J; Yang L; Li L; Gao X; Sun X; Bai J; Liu J; Pu X; Wang Y
Small; 2023 Aug; 19(33):e2301497. PubMed ID: 37086131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
